ACRS · Aclaris Therapeutics, Inc.

This filing reports transformative early clinical data for two pipeline assets—ATI-052 and ATI-2138—representing Aclaris’ strategic pivot toward mechanistically differentiated biologics and oral immunomodulators in high-unmet-need Th2 and T-cell-driven diseases. The full Phase 1a SAD/MAD results for ATI-052 exceed the company’s pre-specified target profile: its ~45-day half-life (based on accumulation ratio at 240 mg weekly dosing), dose-proportional PK, and unprecedented residence time on TSLP (~30–116× longer than tezepelumab or dupilumab comparators) directly enable infrequent dosing—a key commercial and adherence advantage over current biologics. Critically, robust and durable pharmacodynamic effects—including complete inhibition of both TSLP- and IL-4-stimulated CCL17 in human whole blood for ≥5 months at 480 mg—confirm deep, sustained pathway blockade consistent with dual upstream (TSLP) and downstream (IL-4Rα) inhibition. The absence of safety signals, especially conjunctivitis (a known class effect with IL-4Rα inhibitors), strengthens the risk-benefit profile. For ATI-2138, the selection of lichen planus as the lead indication is grounded in mechanistic rationale: LP is a CD8+/Th1-driven interface dermatitis with no FDA-approved therapies, and ATI-2138 uniquely co-inhibits ITK (critical for TCR signaling) and JAK3 (essential for IL-2Rγc cytokine signaling), thereby targeting pathogenic T-cell activation at two nodes. With ~40% of LP patients seeking treatment and a U.S. market opportunity estimated above $1.0 billion, this de novo development path avoids competitive saturation while leveraging expedited regulatory pathways for unmet needs. Collectively, these disclosures validate Aclaris’ R&D engine, de-risk near-term catalysts (H2 2026 Phase 1b readouts), and establish clear paths to Phase 2b programs in asthma and LP by year-end—shifting investor focus from platform feasibility to clinical execution and commercial potential.